Journal
NATURE REVIEWS CANCER
Volume 7, Issue 11, Pages 870-879Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2247
Keywords
-
Categories
Ask authors/readers for more resources
Gene-directed enzyme-prodrug therapy (GDEPT) aims to improve the therapeutic ratio ( benefit versus toxic side-effects) of cancer chemotherapy. A gene encoding a 'suicide' enzyme is introduced into the tumour to convert a subsequently administered non-toxic prodrug into an active drug selectively in the tumour, but not in normal tissues. Significant effects can now be achieved in vitro and in targeted experimental models, and GDEPT therapies are entering the clinic. Our group has developed a GDEPT system that uses the bacterial enzyme carboxypeptidase G2 to convert nitrogen mustard prodrugs into potent DNA crosslinking agents, and a clinical trial of this system is pending.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available